HS 10502
Alternative Names: HS-10502Latest Information Update: 20 Oct 2023
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 09 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT05740956)
- 27 Feb 2023 Jiangsu Hansoh Pharmaceutical plans a phase I trial for Solid tumors (Late-stage disease) in China in April 2023 (PO, Tablet) (NCT05740956)
- 28 Dec 2022 Preclinical trials in Solid tumours in China (PO) prior to December 2022